1.13
-0.02 (-1.74%)
| Penutupan Terdahulu | 1.15 |
| Buka | 1.14 |
| Jumlah Dagangan | 6,014,250 |
| Purata Dagangan (3B) | 22,340,677 |
| Modal Pasaran | 211,306,608 |
| Harga / Jualan (P/S) | 195.00 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 14 Aug 2026 |
| EPS Cair (TTM) | 4.09 |
| Nisbah Semasa (MRQ) | 0.720 |
| Aliran Tunai Operasi (OCF TTM) | -64.05 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -35.91 M |
| Pulangan Atas Aset (ROA TTM) | -122.34% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Bercampur | Menaik |
| Biotechnology (Global) | Bercampur | Menaik | |
| Stok | Outlook Therapeutics, Inc. | Bercampur | Menurun |
AISkor Stockmoo
| Konsensus Penganalisis | NA |
| Aktiviti Orang Dalam | 1.5 |
| Volatiliti Harga | -2.0 |
| Purata Bergerak Teknikal | 0.0 |
| Osilator Teknikal | -0.5 |
| Purata | -0.25 |
|
Outlook Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing and commercializing ONS-5010, a monoclonal antibody, or mAb, for various ophthalmic indications. The Company have received marketing authorization for an ophthalmic formulation of ONS-5010/LYTENAVA (bevacizumab-gamma) for use in treating wet age-related macular degeneration, or wet AMD, in the European Union, and United Kingdom. The product pipeline includes ONS-5010/LYTENAVA which is in total eight NORSES; ONS-5010 Clinical Progress, Unmet Patient Needs, New Ophthalmic Anti-VEGF, and Potential First Line Therapy. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Value |
| % Dimiliki oleh Orang Dalam | 38.31% |
| % Dimiliki oleh Institusi | 16.89% |
Pemilikan
| Nama | Tarikh | Syer Dipegang |
|---|---|---|
| Gilpin Wealth Management, Llc | 30 Jun 2026 | 555,000 |
| Nine Masts Capital Ltd | 31 Mar 2026 | 232,546 |
Tiada data dalam julat masa ini.
Tiada data dalam julat masa ini.
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |